卡博替尼治疗肝癌的多靶点作用及其研究进展  

Multi-Target Effects of Cabozantinib in the Treatment of Hepatocellular Carcinoma and Its Research Progress

作　　者：王佩佩 单亮 谢林虎 WANG Peipei;SHAN Liang;XIE Linhu(Dept.of Pharmacy,the Second People’s Hospital of Hefei,Hefei 230011,China)

机构地区：[1]合肥市第二人民医院药学部,合肥230011

出　　处：《中国医院用药评价与分析》2025年第3期376-380,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：安徽省卫生健康科研项目计划项目(No.AHWJ2023BAc20099)。

摘　　要：该文对卡博替尼在肝细胞癌治疗中的多靶点作用及其最新研究进展进行了系统综述,评估其在抑制肿瘤血管生成、调控肿瘤微环境和抑制肿瘤细胞生长中的疗效,并探讨耐药机制和未来发展方向。通过近年来的文献和临床研究数据,对卡博替尼的分子靶点及其多层次抗肿瘤作用进行解析,总结其在各阶段临床应用的疗效和安全性。同时,探讨其联合治疗的策略、耐药机制和新型给药技术的研究前景。卡博替尼通过抑制血管内皮生长因子受体、肝细胞生长因子受体和AXL受体酪氨酸激酶等多种信号通路,显著抑制肿瘤血管形成、细胞增殖和转移,并优化肿瘤免疫微环境。临床数据显示,其在晚期肝癌多线治疗中显示出较高的疾病控制率和生存获益。然而,随着治疗时间延长,耐药性逐渐显现,且有高血压、手足综合征等不良反应需要管理。卡博替尼在肝癌治疗中展现出多靶点抗肿瘤的潜力,未来研究应着重于耐药机制的解析、新型联合治疗的开发及生物标志物的应用,并探索纳米技术等新型给药方式,以提高疗效和安全性。多途径干预将有助于推动肝癌治疗取得新的突破。This article performs a systematic review on the multi-targeted effects of cabozantinib in the treatment of hepatocellular carcinoma and its latest research progress,so as to evaluate its efficacy in inhibiting tumor angiogenesis,modulating the tumor microenvironment and suppressing tumor cell growth,as well as explore the mechanisms of drug resistance and the direction of future development.Through literature and clinical research data in recent years,this article analyzes the molecular targets and the multilevel anti-tumor effects of cabozantinib,and summarizes its efficacy and safety in various stages of clinical application.Meanwhile,this article investigates the combination therapy strategy,drug resistance mechanism and novel drug delivery technology of cabozantinib.Cabozantinib significantly inhibits tumor angiogenesis,cell proliferation and metastasis,optimizes the tumor immune microenvironment by inhibiting various signaling pathways including vascular endothelial growth factor receptor,hepatocyte growth factor receptor and Anexelekto.c-mesenchymal to epithelial transition factor and AXL.Clinical data indicates that cabozantinib demonstrates high disease control rate and survival benefit in multiline treatment of advanced hepatocellular carcinoma.However,drug resistance emerges as the treatment is prolonged,and adverse effects such as hypertension and hand-foot syndrome need to be managed.Cabozantinib has showed multi-targeted anti-tumor potential in hepatocellular carcinoma treatment,and future studies should focus on the resolution of resistance mechanisms,the development of novel combination therapies and the application of biomarkers,as well as the exploration of nanotechnology and other novel drug delivery ways,so as to improve efficacy and safety.Multi-pathway interventions will help promote new breakthroughs in hepatocellular carcinoma treatment.

关 键 词：卡博替尼 肝细胞癌 多靶点抑制 耐药机制 生物标志物 新型给药技术 

分 类 号：R979.1[医药卫生—药品]